G. Gille
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
G. Gille has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
B. Janetzky
Department of Neurology, Technical University of Dresden, Federal Republic of Germany
2 shared publicationsH. Reichmann
Department of Neurology, Technical University of Dresden, Federal Republic of Germany
2 shared publicationsS.-T. Hung
Institute for Medical Chemistry, Veterinary Medical University, Vienna, Austria
2 shared publicationsW.-D. Rausch
Institute for Medical Chemistry, Veterinary Medical University, Vienna, Austria
2 shared publicationsA. Engfer
1 shared publicationA. Ngyuen
1 shared publication
Latest Publications
- 1 May 2002
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 109 (5-6) , 633-643
Pergolide protects dopaminergic neurons in primary culture under stress conditions
Dopamine agonists are an important therapeutic strategy in the treatment of Parkinson's disease. They postpone the necessity for and reduce the required dose of L-3,4-dihydroxyphenylalanine (L-DOPA) medication thus protecting against the development of motor complications and potential oxidative stress due to L-DOPA metabolism. In primary cultures from mouse mesencephalon we show that pergolide, a preferential D2 agonist enhanced the survival of healthy dopaminergic neurons at low concentrations of 0.001 μM. About 100 fold higher concentrations (0.1 μM) were necessary to partially reverse the toxic effects of 10 μM 1-methyl-4-phenylpyridinium (MPP+). Pergolide was equally effective in preventing the reduction of dopamine uptake induced by 200 μM L-DOPA. Furthermore, between 0.001–0.1 μM it also reduced lactate production thus promoting aerobic metabolism. The present findings suggest that pergolide protects dopaminergic neurons under conditions of elevated oxidative stress.
- 1 May 2002
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 109 (5-6) , 633-643
Pergolide protects dopaminergic neurons in primary culture under stress conditions
Dopamine agonists are an important therapeutic strategy in the treatment of Parkinson's disease. They postpone the necessity for and reduce the required dose of L-3,4-dihydroxyphenylalanine (L-DOPA) medication thus protecting against the development of motor complications and potential oxidative stress due to L-DOPA metabolism. In primary cultures from mouse mesencephalon we show that pergolide, a preferential D2 agonist enhanced the survival of healthy dopaminergic neurons at low concentrations of 0.001 μM. About 100 fold higher concentrations (0.1 μM) were necessary to partially reverse the toxic effects of 10 μM 1-methyl-4-phenylpyridinium (MPP+). Pergolide was equally effective in preventing the reduction of dopamine uptake induced by 200 μM L-DOPA. Furthermore, between 0.001–0.1 μM it also reduced lactate production thus promoting aerobic metabolism. The present findings suggest that pergolide protects dopaminergic neurons under conditions of elevated oxidative stress.
- 1 February 2002
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 109 (2)
Protection of dopaminergic neurons in primary culture by lisuride.
Dopamine agonists play an important role in the treatment of Parkinson's disease by reducing the administration of L-3,4-dihydroxyphenylalanine (L-DOPA). The enzymatic and non-enzymatic conversion of L-DOPA is suspected to increase oxidative stress, which leads to the degeneration of dopaminergic neurons in Parkinson's disease. In primary mouse mesencephalic cultures we show that the dopamine D1/D2 receptor agonist lisuride, in a concentration range of 0.001-1 microM, enhances the survival of dopaminergic neurons, protects against toxicity induced by L-DOPA or 1-methyl-4-phenylpyridinium ion (MPP+) and stimulates 3H-dopamine uptake. Lisuride also reduces anaerobic metabolism during incubation with L-DOPA. The present findings suggest that lisuride may have trophic/survival-promoting properties and potentially reduces oxidative stress.
- 1 February 2002
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 109 (2)
Protection of dopaminergic neurons in primary culture by lisuride.
Dopamine agonists play an important role in the treatment of Parkinson's disease by reducing the administration of L-3,4-dihydroxyphenylalanine (L-DOPA). The enzymatic and non-enzymatic conversion of L-DOPA is suspected to increase oxidative stress, which leads to the degeneration of dopaminergic neurons in Parkinson's disease. In primary mouse mesencephalic cultures we show that the dopamine D1/D2 receptor agonist lisuride, in a concentration range of 0.001-1 microM, enhances the survival of dopaminergic neurons, protects against toxicity induced by L-DOPA or 1-methyl-4-phenylpyridinium ion (MPP+) and stimulates 3H-dopamine uptake. Lisuride also reduces anaerobic metabolism during incubation with L-DOPA. The present findings suggest that lisuride may have trophic/survival-promoting properties and potentially reduces oxidative stress.